LMC’s “Clinical Practice Update in Endocrinology & Diabetes” Conference: SGLT2 inhibitors and cardiovascular risk reduction
Recent cardiovascular outcome trials have demonstrated the cardiovascular, and potentially renal, benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in patients with type 2 diabetes who have established cardiovascular disease. In this video, Dr. Peter Lin and Dr. Ronald Goldenberg discuss the use of SGLT2 inhibitors, and the possibility of their use in non-diabetic individuals.
Peter J. Lin(MD, CCFP)
Ronald Goldenberg(MD, FRCPC, FACE)